Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques
Svanholm, H.; Hørder, M.
Scandinavian Journal of Urology and Nephrology. Supplementum 107: 65-70
1988
ISSN/ISBN: 0300-8886 PMID: 2453920 Document Number: 321523
Immunohistochemical techniques using antibodies to prostate specific antigen (PSA) and prostate specific acid phosphatase (PAP) have greatly increased the feasibility of reliable diagnosis of primary or metastatic prostatic carcinoma. A review of the literature showed the diagnostic specificity of antibodies to PSA or PAP to be 100% and 87-100%, respectively. The corresponding figures for diagnostic sensitivity were 94-100% and 90-100%.
Document emailed within 1 workday
Related Documents
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Goldenberg, D.M.; DeLand, F.H. 1984: Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase Urologic Clinics of North America 11(2): 277-281
Kumamoto, Y.; Tsukamoto, T.; Umehara, T.; Harada, M.; Shimazaki, J.; Fuse, H.; Oshima, H.; Takeuchi, H.; Yoshida, O.; Okada, K. 1990: Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis Hinyokika Kiyo. Acta Urologica Japonica 36(3): 295-305
Oishi, K.; Arai, Y.; Takeuchi, H.; Yoshida, O. 1993: Side effects of estrogen administration to prostatic cancer patients: clinical and statistical survey of 109 prostatic cancer cases of Kyoto University Hospital Hinyokika Kiyo. Acta Urologica Japonica 39(1): 23-28
Vieillefond, A.; Berger, N.; Dauge-Geffroy, M.C.; Saint Andre, J.P. 1993: Prostatic adenosis and dysplasia. what is their definition... and their significance? Are there "precancerous" lesions in prostatic pathology? Annales de Pathologie 13(2): 85-87
Bouffioux, C. 1983: Prostatic cytology. Value of the technic in the diagnosis and surveillance of prostatic carcinomas; viewpoint of the urologist Acta Urologica Belgica 51(1): 56-71
Cecchi, M.; Sepich, C.A.; Pagni, G.L.; Summonti, D.; Ippolito, C.; Di Benedetto, A.; Bertolini, L.; Minervini, R.; Fiorentini, L. 1998: Prostatic endoprosthesis in the treatment of prostatic obstruction: preliminary experience with the new Trestle model Chirurgia Italiana 50(1): 37-40
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Rodríguez Rodríguez, R.; Mayayo Dehesa, T.; Galbis Sanjuan, F.; Burgos Revilla, F.J.; Jiménez Cidre, M.; García González, R. 1996: Chronic prostatic inflammation: a confounding factor in the diagnosis of prostatic cancer Archivos Espanoles de Urologia 49(7): 669-673
Paul, B.D.; Serrano, J.A.; Friedman, A.E.; Sarlos, I.J.; Sternberger, N.J.; Wasserkrug, H.L.; Seligman, A.M. 1977: New agents for prostatic cancer activated specifically by prostatic acid phosphatase Cancer Treatment Reports 61(2): 259-263
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Strohmenger, P. 1980: Prostatic adenoma--prostatic carcinoma. Questions from general practice. II. Therapy Zfa. Zeitschrift für Allgemeinmedizin 56(28): 1793-1797
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Kazama, T.; Mizuno, I.; Takamine, T.; Umeda, K.; Terada, T.; Ishikawa, S.; Fuse, H.; Katayama, T. 1990: Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography Hinyokika Kiyo. Acta Urologica Japonica 36(12): 1423-1427
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187